To really test the health benefits of drinking collagen peptides, I vowed to take it every day for two weeks. I opted for Vital Proteins Unflavored Grass-Fed Collagen Peptides in the blue tub. I got the 20-ounce tub and a box of the stick packs, which were perfect for when I went out of town. I stuck with one scoop from the tub for 35 calories, 9 grams of protein, and 10 grams of collagen (this was the same serving size in the stick packs).
This is a great option for those who are looking to promote a steady and improved release of GH to get the benefits of increases in growth hormone and subsequently Insulin Like Growth Factor -1 (IGF-1) with almost no side effects. This therapy is effectively used for anti-aging purposes as well as those with inflammatory conditions, disease or those who have low IGF-1 levels.
Id do 150mc of ghrp2, 20min later 2-5iu of GH ( as much as you can afford) then be taking albuterol all day long with 25mcg of T3. Peptides fell off the map 1-2 yrs ago, all the good suppliers began to put of shit. Once upon a time you could get LR3 for under 100 bux............like legit stuff. igf DES was around for another year after LR3 went bunk with 95% of places.
A similar clinical study was conducted in obese subjects (METAOD002). In that double-blind placebo-controlled, 4 sequence, 4 period William’s Latin Square design study 23 subjects participated. The subjects were 19 to 50 years old and had a BMI ≥ 35 kg/m2 (range 36 to 67 kg/m2). Each subject received 4 single doses (25, 50 and 100 µg/kg AOD9604 or placebo; single IV infusion doses over 20 minutes), separated by a 7-day washout period.
CJC-1295 10mg (Up to 10 Weeks): Started Wednesday 21 st September 2016 weight 122 kilo. Belly measurement 122cm Thursday 22nd September Weight @ 3pm 118.5 kilo Belly Measurement 117cm Morning and night 3 pumps Stacking with CJC1295 injectable. Lots of energy feel great aches and pains starting to subside.I will be doing a few more courses in the near future. THANKS Peptideclinics.com.au Awesome products. Shane Ridley
Eligible study subjects were admitted after overnight fasting for an outpatient visit at the MGH CRC. Upon admission, two intravenous catheters were placed for phlebotomy and 10 mL/m2 of body‐surface area (BSA)/minute normal saline (0.9 mEq/mL) was infused over 2 hours. Blood pressure, heart rate, and oxygen saturation were measured every 20 minutes during the saline infusion. BSA was calculated according to the DuBois algorithm (BSA (in m2)=0.20247×height (m)0.725×weight (kg)0.425). Venous blood was sampled beginning immediately prior to the start of the infusion and at 40, 80, 120, and 180 minutes after the start of the infusion.
"A doctor is much more likely to prescribe a drug that addresses the underlying metabolic problem," Dr Belyea said. In addition, all of the drugs currently on the market have noticeable side-effects ranging from mood changes to unpleasant effects on the digestive system. The FDA withdrew fenfluramine and dexfenfluramine (Redux), from the market in 1997 after the drugs were linked to heart valve abnormalities.

Figure 2A shows that neither hGH nor AOD9604 had any significant effect on the weight of epididymal adipose tissue in the lean mice. However, in the ob/ob mice, AOD9604 induced a 28% decrease in epididymal adipose tissue mass, and hGH induced a 40% reduction in epididymal adipose tissue mass (P < 0.05). Brown adipose tissue weights were also measured (Fig. 2B). In this tissue, both AOD9604 and hGH induced a reduction in the weight of brown adipose tissue in both the lean and ob/ob mice.
However, both the original GRF (1-29) and the Mod GRF 1-29 required frequent dosages. So a new compound called CJC-1295 was created which was far more stable. This compound was made by adding Lysine – which is a non-peptide, and is also called Drug Affinity Complex or DAC. Since the original Mod GRF 1-29 does not contain DAC, it is named as CJC-1295 without DAC. However, the actual CJC-1295 is not only difficult, but also very expensive to produce. This is why it is not produced or used extensively. The Mod GRF 1-29 is far easier and cheaper to produce.

In a statement to Fairfax Media on Thursday, Calzada Ltd said: ''The US generally recognised as safe 'GRAS' status is being explored as another viable commercial path for the company to pursue to potentially derive early revenue. Whilst AOD-9604 was not successful in human trials aimed at obesity, the Company believes there is sufficient efficacy data to enable a potential food, drink or dietary supplement product to be successfully marketed in the US.''
There is the potential for the side effects associated with use of growth hormone when growth hormone secretagogues are used, particularly if the use is not under medical supervision. There are limited data on the safety of intravenous and subcutaneous use of AOD-9604 and on the long-term oral use of AOD-9604 in doses in excess of those used in clinical trials.
Nevertheless, the hypothesis that AOD9604 does not activate the hGH/IGF-1 axis had to be tested in humans. The studies presented here confirm the in-vitro results. In these studies no clinically relevant changes of IGF-1 levels were observed and no differences to the placebo treatment were found. Together with the lack of any other symptoms associated with known IGF-1 mediated effects, such as sodium retention, tissue oedema, hypertension, or impaired glucose tolerance, the results demonstrate that AOD9604 does not activate the hGH/IGF-1 pathway and therefore has no growth promoting effect.
Prof. Louis J Aronne MD, President of the North American Association for the Study of Obesity and a member of Metabolic’s Clinical Advisory Panel, said: "This is an exciting new approach to a problem which has defied easy solutions. We will need many different treatments if we are going to manage obesity successfully, in much the same way we have many treatments available for diabetes and hypertension".
Five public submissions were received. Many of the submissions referred to the article published in the New England Journal of Medicine (NEJM) when giving their reasons for either supporting or rejecting the proposal. Some submissions also noted that a similar proposal is to be considered by an upcoming meeting of the Medicines Classification Committee (MCC) in New Zealand.
The male β3-KO mice and wild-type (WT) that were used in this study were offspring of animals provided by Dr. Bradford Howell (Beth Israel Hospital, Harvard Medical School, Boston, MA). The animals were bred and housed in the central animal house facility (Monash University). For chronic studies, animals were housed in the Departmental Animal Facility (Biochemistry, Monash University). For acute energy expenditure studies, animals were transported to the Department of Medicine (University of Melbourne), acclimatized, and killed following experimentation. The WT andβ 3-KO mice genotype were verified by breeding records and RT-PCR analysis performed in the laboratory of Professor Roger Summers.

"Paracetamol is used worldwide for its analgesic and antipyretic actions and has been available in Australia since 1956. Caffeine is a stimulant and acts as an analgesic adjuvant, whereby it augments the analgesic effects of pain relievers such as paracetamol. The combination of paracetamol/caffeine (2x500mg/65mg) is indicated for temporary relief of pain and discomfort associated with headaches, tension headaches, osteoarthritis, arthritis, cold and flu symptoms, toothache, dental procedures, muscular aches, sore through and period pain. It also reduces fever.

Paracetamol is distinct from non-steroidal anti-inflammatory drugs (NSAIDs). It is a para-acetylaminophenol with both analgesic and antipyretic properties. Originally synthesized in the 1880s and first released for use on prescription in 1955 in the USA and on 1956 in UK. It has been available in most countries, without prescription, for many years. Recent data suggests it acts via a central mechanism, whereby it is deacetylated to 4-aminophenyl and then conjugated with arachidonic acid to form N-arachidonoylphenylamine which is an exogenous cannabinoid (Hogestatt ED et al. 2005).
It is also notable that the rise in absolute concentrations of ANP and Nt‐proANP after weight loss surgery was comparable to that observed with a 2‐L saline infusion. This observation suggests that the magnitude of obesity‐induced alteration in natriuretic peptide production is physiologically relevant. The slope of the natriuretic peptide response to saline challenge was similar before and after weight loss, suggesting that obesity does not blunt the responsiveness of the natriuretic peptide axis to salt challenge, but rather alters the “set point.”
I have not used IGF-1 but I have used a stack of Ipamorelin and CJC 1295 no DAC. I did not do any lab tests before, during or after but definitely noticed increased fat loss and better sleep. I was not trying to increase muscle so there was no change to speak of for me. But you are not recommending their use even without IGF-1, is that correct? I do not compete in anything so WADA is not a concern.
Prof. Gary Wittert, Adelaide-based Principal Investigator on the study, said: “As the world’s first drug with a metabolic mechanism of action AOD9604 could occupy a unique position among the options available to doctors for the management of obesity. It is pleasing that the invention and its development from the laboratory bench has been an all–Australian effort.”

Other studies have had similar results with regards to the effect of collagen supplementation in helping to promote fullness. One study consisted of 24 healthy adults testing the satiety effects of various protein supplements. The subjects had two breakfast meals with specific types of protein in each: one meal had alpha-lactalbumin, gelatin, or gelatin + tryptophan (TRP) (Breakfast 1) and the other meal contained casein, soy, whey, or whey + glycomacropeptide (GMP) (Breakfast 2). The study found that Breakfast 1, which included gelatin (collagen), was 40% more satiating than Breakfast 2, which did not contain gelatin or collagen. Additionally, the participants who ate Breakfast 1 with gelatin ended up consuming less calories for lunch. Researchers concluded that gelatin increases satiety, which can lead to subsequent reduced energy intake, thereby promoting weight loss (2).

Obesitrol has been one of the best-selling diet pills for the last 3 years! Why do users love Obesitrol so much? It is simple, Obesitrol is an all-natural formula. With 5 science-backed ingredients, Obesitrol helps you reach your weight-loss goals with a formulation including ingredients shown to increase thermogenesis, boost energy and deliver significant weight loss results. Obesitrol has been one of this year’s best-selling diet pills because it provides a fantastic weight loss formula for UNDER $30! To top if off, it’s backed by a no-nonsense 90 Day Money Back Guarantee. Read More

If using it with CJC 1295, you can experience a correlation in increased muscle mass levels. With longer release periods, greater results are achievable. So, if you want to gain more muscle mass, or if you simply want to increase levels of lean muscle mass, you are going to realize these possibilities when you incorporate the use of Ipamorelin into your daily regimen.


AOD-9604 is a variant of growth hormone which has fat burning properties and may be used by athletes to increase power to weight ratios by better utilisation of fat stores. During clinical trials it was also found to have an anabolic effect on cartilage tissue and may promote cartilage creation and repair and have a capacity to enhance muscle formation.
Obesitrol has been one of the best-selling diet pills for the last 3 years! Why do users love Obesitrol so much? It is simple, Obesitrol is an all-natural formula. With 5 science-backed ingredients, Obesitrol helps you reach your weight-loss goals with a formulation including ingredients shown to increase thermogenesis, boost energy and deliver significant weight loss results. Obesitrol has been one of this year’s best-selling diet pills because it provides a fantastic weight loss formula for UNDER $30! To top if off, it’s backed by a no-nonsense 90 Day Money Back Guarantee. Read More
The β3-AR and actin primers were intron spanning to potentially reveal contaminant genomic DNA (none observed). Reverse primers were labeled before the PCR in a reaction mixture containing 120 pmol oligonucleotide, 70 μCi[γ -33P]ATP (Bresagen, Adelaide, Australia), 1× One-Phor-All Plus buffer (Pharmacia Biotech, Uppsala, Sweden) and 20 U T4 polynucleotide kinase (Pharmacia Biotech) in a volume of 40 μl. Following incubation at 37 C for 30 min, reactions were diluted to 100 μl with H2O and heated at 90 C for 2 min.
Proposed to be the future of medicine, these links of amino acids are not just treating chronic diseases but are providing a cure, and it’s only a matter of time before they become the new standard of preventative healthcare. Peptides are legal and they are here to stay. So now that we have debunked many of the myths on peptides, you be the judge. Whether you are on board or still a sceptic, the use of peptides is undeniably increasing and it’s no surprise as to why.
Raising GH levels with any peptide would accelerate fat loss obviously but if looking at strictly fat loss HGH frag 176-191 and AOD9604 (frag 177-191) are the fat loss peps. They are the part of the HGH amino acid sequence that initiates lipolysis. I personally like Hexarelin dosed 3x a day, it is the strongest ghrp and doesn't have any effect on hunger so it works great for fat loss and dieting for me.
There were no significant changes in IGF-1 values observed during 24 hours following any AOD9604 dose compared with placebo. No significant differences in glucose levels were observed following AOD9604 administration compared with placebo with the exception of one isolated time point (8% increase 12 hour post treatment in one subject receiving 54 mg AOD09604). There were no clinically significant observable trends in vital signs, physical examinations, abnormalities noted in the ECG measurements, or findings in the safety-related laboratory tests throughout the study.
These results also demonstrate that, unlike hGH, AOD9604 has no negative effect on carbohydrate metabolism. This was previously demonstrated in mice. Chronic administration of hGH to ob/ob mice depressed glucose oxidation and increase plasma glucose levels. AOD9604 had no such effects, no changes in circulating plasma glucose in either lean nor obese ob/ob mice have been observed [20]. AOD9604 did not cause hyperglycemia or affect insulin sensitivity in rats and mice [18, 20].
Meanwhile, more Phase II clinical studies are planned for the next 12 months including a study examining the efficacy of oral administration, which has been shown to be effective in laboratory animals. This will be followed by a weight loss study. Confirmation of the age-effect will also be sought. Metabolic aims to start a two-year Phase III studies program in 2003, which would not place final FDA approval before 2005.

Background: The human growth hormone (hGH) has properties making it a potential candidate to treat obesity, however safety issues limit its long-term use. AOD9604 is a peptide fragment of the C-terminus of hGH (Tyr-hGH177-191), which harbors the fat reducing activity of hGH, without its negative effects. In this paper the safety data of AOD9604 obtained in clinical trials are summarized.
Smeath says he turns patients away on a weekly basis. "[Particularly] if a patient comes and asks me for a specific peptide and it's not right for them. It's the same as if an anti-biotic was unsuitable for a patient, we don't just prescribe it." He says a lot of people prefer face-to-face contact with the prescribing doctor, but if geography restricts them, phone and Skype sessions also take place.
×